Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Bell, Noah,Carreras, Christopher,Charmot, Dominique,Chen, Tao,Leadbetter, Michael,Jacobs, Jeffrey,Lewis, Jason
申请号：
AU2013304813
公开号：
AU2013304813A1
申请日:
2013.08.20
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist- induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
